electronRx to Launch Pulmonary Disease App for Remote Lung Function Monitoring

electronRx, a leading digital medicine and biomarker company driving healthcare through pulmonary innovation, will launch purpleDx, a cardiopulmonary assessment app built to medical device standards, at CES 2025. The app was developed in collaboration with several respiratory clinics and the company’s recent charity partner, the European Pulmonary Hypertension Association. 

The technology enables chronic respiratory disease (CRD) patients to detect and monitor digital biomarkers of lung function at home while providing clinicians with real-time data to customize treatment plans and help improve patient outcomes.

Dr Bipin Patel, CEO and Founder, electronRx, said: “Integrating digital biomarker monitoring with prescribed medications embodies a revolutionary approach to healthcare management. Our purpleDx technology transforms a mobile phone into a powerful tool that will not only enable patients to measure and quantify lung health but share these invaluable and potentially life-saving insights with their healthcare providers. This will empower them to manage chronic diseases more effectively and tailor treatments for individuals, leading to enhanced therapeutic outcomes.”

purpleDx is a smartphone app with an accompanying clinical dashboard to support clinicians in detecting, monitoring, and treating pulmonary diseases, including asthma, chronic obstructive pulmonary disease, interstitial lung disease, and pulmonary hypertension. 

These digital apps are built onto the iPhone and use the camera to capture and measure the blood flow around the face that is invisible to the human eye. A 30 to 60-second measurement captures data points that can then be converted into digital biomarkers to capture a range of physiological measurements.

“We’re incorporating the latest clinical insights and data into purpleDx to ensure our platform remains at the forefront of technological innovation and continues to drive advancements in the management and treatment of CRDs worldwide,” Patel added.

electronRx’s proprietary suite of digital solutions is dedicated to improving the lives of people with breathing disorders using smartphone technology to measure changes in cardiac and pulmonary functions to support them in making informed interventions.